Business Wire

BRIGHTCOVE

18.8.2020 15:02:14 CEST | Business Wire | Press release

Share
Streamed Video Content Dominates Media and Entertainment Consumption in Europe According to the Brightcove Q2 2020 Global Video Index

Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today published the Brightcove Q2 2020 Global Video Index Entertainment and Media Edition , which found that OTT streaming of entertainment content continued to dominate, even as governments began loosening stay-at-home restrictions. The data suggests that consumers’ media consumption habits may be permanently shifting away from linear TV, cementing streaming as the go-to choice for entertainment viewing.

Brightcove’s Q2 2020 Global Video Index analyzes hundreds of billions of recent data points from Brightcove’s customers globally to provide insights into how viewers are watching video content. The Q2 data shows that consumption of news and entertainment content nearly doubled (40%) from Q1 (23%) – a significant finding considering Q2 typically sees slower growth in video viewing compared to Q1. Looking at the first half of 2020 compared to 2019, the number of views overall is up more than 30%.

“Consumers in Europe continue to remain glued to their smartphones as we’ve seen mobile consumption surge for two consecutive quarters now,” said Jim O’Neill, Principal Analyst and Author of Brightcove’s Global Video Index. “This, in addition to video views on connected TVs continuing to grow, indicates consumers increasingly are turning to streaming devices to view entertainment content. This shift in consumption will only strengthen as connected TVs inevitably replace computers as the second preferred device for consumption – following mobile.”

Where consumers choose to view their content is also shifting. Connected TVs (CTVs) saw the most growth in Q2 (160% year-over-year), indicating a resurgence in larger screens as the viewing medium of choice for entertainment.

Other notable findings from the Brightcove Q2 2020 Global Video Index that are specific to Europe include:

  • Consumption peaked despite regions reopening. Video views were up 52% in Q2.
  • Smartphones are continuing to see spikes in consumption. Views on mobile devices increased by 69%, following Q1 in which mobile views more than doubled. Smartphones were also dominant across all content lengths in Q2.
  • CTVs saw a surge in use. Video views on CTVs were up 42% in Q2; 45% in April, 37% in May, and 44% in June. For the first six months of the year, views on CTVs grew 49%, the second biggest gain among devices. CTV viewers also watched content more than 3x as long as on any other device.

“2020 has become video’s evolutionary moment, and streaming entertainment video content is one area where we will continue to see growth,” said Jeff Ray, Brightcove CEO. “The crisis has impacted people at an emotional and financial level, making the need for human connection through video content more crucial than ever. We’re seeing this play out with the rise of streaming services subscriptions, indicating that the future of entertainment consumption lies in connected and mobile devices – linear television could soon be of the past.”

To download the complete Brightcove Q2 2020 Global Video Index Entertainment and Media Edition inclusive of all data, visit: https://www.brightcove.com/en/video-index

To learn more about this quarter’s findings, tune into an exclusive webinar with Jim O’Neill on September 15th. To register, visit: https://get.brightcove.com/global-video-index-2020-q2/

About the Global Video Index

Brightcove’s Global Video Index assesses more than 400 billion anonymized data points from Brightcove’s thousands of customers each quarter, drawing industry insights that can help guide strategic and tactical decisions for businesses of all sizes.

About Brightcove Inc. (NASDAQ: BCOV)

We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.

Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye